US breakthrough designation for ligelizumab in chronic spontaneous urticaria
In a Phase IIb trial, more patients experienced complete resolution of hives with ligelizumab compared to Xolair
Read More
Tag: Ligelizumab
Ligelizumab continues to trump Xolair in chronic spontaneous urticaria
The Novartis drug can bind to IgE with an 88-fold higher affinity than Xolair.
Read More
Ligelizumab trumps Xolair in spontaneous urticarial trial
The drug achieved complete control of hives in 51% and 42% of patients, compared with 26% of patients treated with Xolair.
Read More
- Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
- Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
